LAS VEGAS, NV / ACCESSWIRE / January 7, 2016 / Endonovo Therapeutics, Inc. (OTCQB:ENDV), an innovative biotechnology company developing bioelectronics-based products and therapies for regenerative medicine, recently paid off a convertible promissory note with Vis Vires Group, Inc. for $56,590.85 avoiding any immediate dilution.
This is exciting for investors and traders alike because ENDV has been trading on a relatively low float. A low float means that the stock’s price will go up very easily on lower volume as long as they continue to avoid dilution like they have been.
One example of the stock's ability to move on relatively low volume came about a month ago, as the stock went from 10 cents a share to just over 75 cents. Profit takers brought the stock to around its current price, where savvy investors are loading up for the next pop. This could come at any moment, so it’s ideal for traders to take a look at the company as soon as possible.
ENDV’s next step is securing more financing and it is currently working with several new investors as well as a top tier New York Investment Bank to secure a larger round of financing to complete its pre-clinical work and explore licensing and potential revenue producing applications of its technologies.
Alan Collier, Chairman and CEO, commented, "We remain committed to increasing shareholder value and avoiding immediate shareholder dilution. This represents a significant first step toward consolidating and eliminating our convertible debt. As a result, this provides the company flexibility as it continues to work on obtaining a larger round of institutional financing. We are vigilant when it comes to protecting our shareholders' interest while we progress towards the commercialization of the company's two leading platforms."
Endonovo Therapeutics, Inc. is an innovative biotechnology company developing bioelectronic devices and therapies for regenerative medicine. Endonovo's Immunotronics(TM) platform is a non-invasive, non-implantable bioelectronic device for treating/preventing vital organ failure through the reduction of inflammation, cell death and the promotion of regeneration. Endonovo's Cytotronics(TM) platform provides for a method of expanding and manipulating cells using simulated microgravity and Time-Varying Electromagnetic Fields (TVEMF) for tissue engineering and cell therapies. The Company's initial concentration is on the treatment of acute and chronic inflammatory conditions of the liver using its proprietary Immunotronics(TM) platform.
In other biotech news:
A few other biotechs have been turning heads; Actinium Pharmaceuticals, Inc. (ATNM), Synta Pharmaceuticals Corp. (NASDAQ: SNTA), Chimerix Inc (NASDAQ:CMRX) and Arena Pharmaceuticals, Inc. (ARNA).
In the biotech industry it doesn’t take much to cause a major price appreciation, as noted before, ENDV’s anti-dilution move is huge for potential investors and we believe as the company begins to find more of an audience this lack of dilution will create the environment for major share value appreciation, and is a reason why investors should begin taking a close look now.
Legal Disclaimer
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns Microcapspeculators.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC. which owns, Microcapspeculators.commay from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC. which owns, Microcapspeculators.commay be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. ACR Communication, LLC has been compensated a total of $6,000 cash by A non-affiliate third party of ENDV.
Contact:
SOURCE: ACR Communication, LLC
